Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection - PubMed (original) (raw)
Comparative Study
Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection
Susan C Fagan et al. Exp Neurol. 2004 Apr.
Abstract
Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.
Similar articles
- Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment.
Wasserman JK, Zhu X, Schlichter LC. Wasserman JK, et al. Brain Res. 2007 Nov 14;1180:140-54. doi: 10.1016/j.brainres.2007.08.058. Epub 2007 Sep 5. Brain Res. 2007. PMID: 17919462 - Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller KM, Carty ML, Reinebrant HE, Wixey JA. Buller KM, et al. J Neurosci Res. 2009 Feb 15;87(3):599-608. doi: 10.1002/jnr.21890. J Neurosci Res. 2009. PMID: 18831005 Review. - Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats.
Nicolazzo JA, Nguyen TT, Katneni K, Steuten JA, Smith G, Jarrott B, Callaway JK, Charman SA. Nicolazzo JA, et al. J Pharm Pharmacol. 2008 Feb;60(2):171-8. doi: 10.1211/jpp.60.2.0005. J Pharm Pharmacol. 2008. PMID: 18237464 - Neuroprotection by nitrous oxide: facts and evidence.
Haelewyn B, David HN, Rouillon C, Chazalviel L, Lecocq M, Risso JJ, Lemaire M, Abraini JH. Haelewyn B, et al. Crit Care Med. 2008 Sep;36(9):2651-9. doi: 10.1097/CCM.0b013e318183f646. Crit Care Med. 2008. PMID: 18679119 - Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.
Cook AM, Whitlow J, Hatton J, Young B. Cook AM, et al. Expert Opin Drug Saf. 2009 Jul;8(4):411-9. doi: 10.1517/14740330903066742. Expert Opin Drug Saf. 2009. PMID: 19548859 Review.
Cited by
- Tetracyclines and pain.
Bastos LF, de Oliveira AC, Watkins LR, Moraes MF, Coelho MM. Bastos LF, et al. Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):225-41. doi: 10.1007/s00210-012-0727-1. Epub 2012 Jan 27. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22282331 Review. - Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.
Rodriguez CI, Bender J Jr, Marcus SM, Snape M, Rynn M, Simpson HB. Rodriguez CI, et al. J Clin Psychiatry. 2010 Sep;71(9):1247-9. doi: 10.4088/JCP.09l05805blu. J Clin Psychiatry. 2010. PMID: 20923629 Free PMC article. - Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.
Poloyac SM, Bertz RJ, McDermott LA, Marathe P. Poloyac SM, et al. J Neurotrauma. 2020 Nov 15;37(22):2435-2444. doi: 10.1089/neu.2018.6295. Epub 2019 Apr 10. J Neurotrauma. 2020. PMID: 30816062 Free PMC article. Review. - Reactive microglia after taste nerve injury: comparison to nerve injury models of chronic pain.
Bartel DL, Finger TE. Bartel DL, et al. F1000Res. 2013 Feb 28;2:65. doi: 10.12688/f1000research.2-65.v1. eCollection 2013. F1000Res. 2013. PMID: 24358861 Free PMC article. - Protective Effect of Minocycline Against Ketamine-Induced Injury in Neural Stem Cell: Involvement of PI3K/Akt and Gsk-3 Beta Pathway.
Lu Y, Lei S, Wang N, Lu P, Li W, Zheng J, Giri PK, Lu H, Chen X, Zuo Z, Liu Y, Zhang P. Lu Y, et al. Front Mol Neurosci. 2016 Dec 20;9:135. doi: 10.3389/fnmol.2016.00135. eCollection 2016. Front Mol Neurosci. 2016. PMID: 28066173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources